Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul>
<li>Cencora has entered a new phase in its healthcare-services strategy with the signing of a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion, a move that would fold EyeSouth’s affiliated retina physicians into Retina Consultants of America, or RCA.</li>
<li>The announcement came as the company reaffirmed fiscal 2026 guidance and then, shortly after, reported a strong first quarter of fiscal 2026 marked by 12% adjusted operating income growth, 9% adjusted diluted EPS growth, and increased full-year operating income guidance following the closing of its OneOncology transaction.</li>
<li>Management’s commentary also offered a useful read-through for the EyeSouth deal: Cencora has been explicit that pharmaceutical-centric management services organizations, or MSOs, are central to its strategy, and RCA has already outperformed expectations in volume, research, and physician additions.</li>
</ul>


Cencora has entered a new phase in its healthcare-services strategy with the signing of a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion, a move that would fold EyeSouth’s affiliated retina physicians into Retina Consultants of America, or RCA.
The announcement came as the company reaffirmed fiscal 2026 guidance and then, shortly after, reported a strong first quarter of fiscal 2026 marked by 12% adjusted operating income growth, 9% adjusted diluted EPS growth, and increased full-year operating income guidance following the closing of its OneOncology transaction.
Management’s commentary also offered a useful read-through for the EyeSouth deal: Cencora has been explicit that pharmaceutical-centric management services organizations, or MSOs, are central to its strategy, and RCA has already outperformed expectations in volume, research, and physician additions.


Cencora Takeover Twist: How EyeSouth Could Fuel A Specialty Pharma Surge!